{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:43:24Z","timestamp":1794015804934,"version":"4.8.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Liver Research"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.livres.2024.05.004","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T11:54:40Z","timestamp":1717242880000},"page":"83-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Hepatitis B virus as a risk factor for hepatocellular carcinoma: There is still much work to do"],"prefix":"10.1016","volume":"8","author":[{"given":"Walaa","family":"Abdelhamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3396-6894","authenticated-orcid":false,"given":"Mohamed","family":"El-Kassas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.livres.2024.05.004_bib1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/jvh.13800","article-title":"Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry","volume":"30","author":"Younossi","year":"2023","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.livres.2024.05.004_bib2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/gutjnl-2021-324915","article-title":"Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database","volume":"72","author":"Vitale","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.livres.2024.05.004_bib3","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2024.05.004_bib4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.livres.2024.05.004_bib5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.livres.2024.05.004_bib6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3138\/canlivj-2023-0003","article-title":"Hepatitis B virus genotypes influence clinical outcomes: a review","volume":"6","author":"Fernandes da Silva","year":"2023","journal-title":"Can Liver J"},{"key":"10.1016\/j.livres.2024.05.004_bib7","doi-asserted-by":"crossref","first-page":"a021436","DOI":"10.1101\/cshperspect.a021436","article-title":"Hepatitis B virus genotypes and variants","volume":"5","author":"Lin","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.livres.2024.05.004_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2023.101360","article-title":"Hepatitis-B virus: replication cycle, targets, and antiviral approaches","volume":"63","author":"Nasser","year":"2023","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.livres.2024.05.004_bib9","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/s41388-020-01593-5","article-title":"C-terminal truncated HBx initiates hepatocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism","volume":"40","author":"Zhang","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.livres.2024.05.004_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1322892","article-title":"Role of hepatitis B virus non-structural protein HBx on HBV replication, interferon signaling, and hepatocarcinogenesis","volume":"14","author":"Wang","year":"2023","journal-title":"Front Microbiol"},{"key":"10.1016\/j.livres.2024.05.004_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jiph.2019.08.004","article-title":"Moving towards hepatitis B elimination in Gulf Health Council states: from commitment to action","volume":"13","author":"Al Awaidy","year":"2020","journal-title":"J\u00a0Infect Public Health"},{"key":"10.1016\/j.livres.2024.05.004_bib12","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/ije\/dyaa253","article-title":"The global burden of chronic hepatitis B virus infection: comparison of country-level prevalence estimates from four research groups","volume":"50","author":"Schmit","year":"2021","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.livres.2024.05.004_bib13","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S2468-1253(22)00050-4","article-title":"Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review","volume":"7","author":"Alberts","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2024.05.004_bib14","article-title":"Hepatocellular carcinoma in Africa: challenges and opportunities","volume":"9","author":"El-Kassas","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.livres.2024.05.004_bib15","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.livres.2024.05.004_bib16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.livres.2024.05.004_bib17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/epirev\/mxj009","article-title":"Hepatitis B virus infection: epidemiology and vaccination","volume":"28","author":"Shepard","year":"2006","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.livres.2024.05.004_bib18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.livres.2024.05.004_bib19","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Tr\u00e9po","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.livres.2024.05.004_bib20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/pathogens13040291","article-title":"Prospects for controlling hepatitis B globally","volume":"13","author":"Soriano","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.livres.2024.05.004_bib21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ijc.1456","article-title":"International trends and patterns of primary liver cancer","volume":"94","author":"McGlynn","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.livres.2024.05.004_bib22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.livres.2024.05.004_bib23","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/jvh.13060","article-title":"Awareness of chronic viral hepatitis in the United States: an update from the national health and nutrition examination survey","volume":"26","author":"Kim","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.livres.2024.05.004_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7201a1","article-title":"Screening and testing for hepatitis B virus infection: CDC recommendations - United States, 2023","volume":"72","author":"Conners","year":"2023","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.livres.2024.05.004_bib25","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S2468-1253(19)30042-1","article-title":"Hepatitis B virus infection in children and adolescents","volume":"4","author":"Indolfi","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2024.05.004_bib26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41124-017-0025-0","article-title":"Highlights from the 3rd international HIV\/viral hepatitis Co-infection meeting - HIV\/viral hepatitis: improving diagnosis, antiviral therapy and access","volume":"2","author":"Maponga","year":"2017","journal-title":"Hepatol Med Policy"},{"key":"10.1016\/j.livres.2024.05.004_bib27","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews","volume":"378","author":"Nelson","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.livres.2024.05.004_bib28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-S4-05","article-title":"The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective","volume":"15","author":"Venook","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.livres.2024.05.004_bib29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"Perz","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2024.05.004_bib30","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1002\/hep.22962","article-title":"Hepatitis B and hepatocellular carcinoma","volume":"49","author":"Di Bisceglie","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2024.05.004_bib31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.21037\/jgo.2017.03.14","article-title":"Viral hepatitis and hepatocellular carcinoma: etiology and management","volume":"8","author":"Zamor","year":"2017","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.livres.2024.05.004_bib32","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.3949\/ccjm.76.s3.02","article-title":"Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment","volume":"76","author":"Sherman","year":"2009","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.livres.2024.05.004_bib33","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.livres.2024.05.004_bib34","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.3748\/wjg.v20.i20.6252","article-title":"Molecular mechanisms of gender disparity in hepatitis B virus-associated hepatocellular carcinoma","volume":"20","author":"Liu","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.livres.2024.05.004_bib35","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.46.3.420","article-title":"Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep)","volume":"46","author":"Fattovich","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.livres.2024.05.004_bib36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.livres.2024.05.004_bib37","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","article-title":"High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load","volume":"142","author":"Tseng","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.livres.2024.05.004_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.830741","article-title":"Hepatitis B virus pregenomic RNA reflecting viral replication in distal non-tumor tissues as a determinant of the stemness and recurrence of hepatocellular carcinoma","volume":"13","author":"Xiao","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.livres.2024.05.004_bib39","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1136\/gut.2003.033324","article-title":"Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma","volume":"53","author":"Chan","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.livres.2024.05.004_bib40","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1053\/j.gastro.2004.09.048","article-title":"Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma","volume":"127","author":"Ni","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.livres.2024.05.004_bib41","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jhep.2020.07.025","article-title":"aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis","volume":"73","author":"Fan","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2024.05.004_bib42","first-page":"297","article-title":"Risk assessment and management of hepatocellular carcinoma occurrence in patients with chronic hepatitis B in the era of antiviral therapy (in Chinese)","volume":"29","author":"Xin","year":"2021","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"10.1016\/j.livres.2024.05.004_bib43","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2024.05.004_bib44","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1016\/j.cgh.2021.02.040","article-title":"Hepatocellular carcinoma prediction models in chronic hepatitis B: a systematic review of 14 models and external validation","volume":"19","author":"Wu","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2024.05.004_bib45","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00000441-197509000-00025","article-title":"Purified and inactivated human hepatitis B vaccine: progress report","volume":"270","author":"Hilleman","year":"1975","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.livres.2024.05.004_bib46","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/jama.1986.03380070075022","article-title":"The safety of the hepatitis B vaccine. Inactivation of the AIDS virus during routine vaccine manufacture","volume":"256","author":"Francis","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.livres.2024.05.004_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.35","article-title":"Hepatitis B virus infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.livres.2024.05.004_bib48","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/S0168-8278(03)00152-1","article-title":"Hepatitis B vaccines","volume":"39","author":"Shouval","year":"2003","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2024.05.004_bib49","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1080\/21645515.2016.1274473","article-title":"Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine","volume":"13","author":"Van Damme","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.livres.2024.05.004_bib50","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.4254\/wjh.v7.i18.2127","article-title":"Three decades of hepatitis B control with vaccination","volume":"7","author":"Meireles","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.livres.2024.05.004_bib51","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S0140-6736(05)65598-5","article-title":"Global status of hepatitis B immunisation","volume":"348","author":"Kane","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.livres.2024.05.004_bib52","first-page":"1","article-title":"Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP)","volume":"40","year":"1991","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.livres.2024.05.004_bib53","first-page":"11","article-title":"Global advisory group--Part I","volume":"67","year":"1992","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.livres.2024.05.004_bib54","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1473-3099(02)00315-8","article-title":"Global control of hepatitis B virus infection","volume":"2","author":"Kao","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.livres.2024.05.004_bib55","first-page":"61","article-title":"Implementation of hepatitis B birth dose vaccination \u2013 worldwide, 2016","volume":"93","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.livres.2024.05.004_bib56","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1093\/infdis\/jiaa668","article-title":"Hepatitis B vaccines","volume":"224","author":"Pattyn","year":"2021","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.livres.2024.05.004_bib57","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1016\/j.vaccine.2016.03.060","article-title":"Progress towards hepatitis B prevention through vaccination in the Western Pacific, 1990-2014","volume":"34","author":"Wiesen","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.livres.2024.05.004_bib58","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1057\/s41271-016-0002-7","article-title":"Transforming our world: implementing the 2030 agenda through sustainable development goal indicators","volume":"37","author":"Lee","year":"2016","journal-title":"J\u00a0Public Health Policy"},{"key":"10.1016\/j.livres.2024.05.004_bib59","article-title":"Viral hepatitis and liver cancer","volume":"372","author":"Ringelhan","year":"2017","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.livres.2024.05.004_bib60","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/v9040075","article-title":"HBV DNA integration: molecular mechanisms and clinical implications","volume":"9","author":"Tu","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.livres.2024.05.004_bib61","doi-asserted-by":"crossref","first-page":"8710","DOI":"10.1128\/JVI.72.11.8710-8717.1998","article-title":"Infection of ducklings with virus particles containing linear double-stranded duck hepatitis B virus DNA: illegitimate replication and reversion","volume":"72","author":"Yang","year":"1998","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.livres.2024.05.004_bib62","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.virol.2015.02.031","article-title":"Molecular biology of hepatitis B virus infection","volume":"479\u2013480","author":"Seeger","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.livres.2024.05.004_bib63","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/hep.27722","article-title":"Characterization of the genotype and integration patterns of hepatitis B virus in early- and late-onset hepatocellular carcinoma","volume":"61","author":"Yan","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2024.05.004_bib64","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/abbs\/gmr048","article-title":"The role of hepatitis B virus X protein is related to its differential intracellular localization","volume":"43","author":"Ma","year":"2011","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"10.1016\/j.livres.2024.05.004_bib65","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.semcancer.2014.01.004","article-title":"Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma","volume":"26","author":"Shlomai","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.livres.2024.05.004_bib66","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s005350170027","article-title":"Hepatitis B virus X protein: a multifunctional viral regulator","volume":"36","author":"Murakami","year":"2001","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.livres.2024.05.004_bib67","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.canlet.2010.09.018","article-title":"Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate Wnt\/\u03b2-catenin signaling","volume":"300","author":"Hsieh","year":"2011","journal-title":"Cancer Lett"},{"key":"10.1016\/j.livres.2024.05.004_bib68","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.livres.2024.05.004_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001624","article-title":"Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis","volume":"11","author":"Singal","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.livres.2024.05.004_bib70","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","article-title":"Randomized controlled trial of screening for hepatocellular carcinoma","volume":"130","author":"Zhang","year":"2004","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.livres.2024.05.004_bib71","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/jvh.13778","article-title":"Hepatocellular carcinoma and hepatitis C virus treatments: the bold and the beautiful","volume":"30","author":"Abdelhamed","year":"2023","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.livres.2024.05.004_bib72","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2024.05.004_bib73","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2024.05.004_bib74","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol Int"},{"key":"10.1016\/j.livres.2024.05.004_bib75","doi-asserted-by":"crossref","DOI":"10.1111\/hepr.12464","article-title":"Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan society of hepatology 2013 update (3rd JSH-HCC Guidelines)","volume":"45","author":"Kokudo","year":"2015","journal-title":"Hepatol Res"},{"key":"10.1016\/j.livres.2024.05.004_bib76","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.3390\/diagnostics13162631","article-title":"Nonalcoholic fatty liver disease-related hepatocellular carcinoma: the next threat after viral hepatitis","volume":"13","author":"Salaheldin","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.livres.2024.05.004_bib77","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/a-1862-9088","article-title":"Nonalcoholic fatty liver disease: current global burden","volume":"42","author":"El-Kassas","year":"2022","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.livres.2024.05.004_bib78","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/annonc\/mdu020","article-title":"Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies","volume":"25","author":"Turati","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.livres.2024.05.004_bib79","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2024.05.004_bib80","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.livres.2024.05.004_bib81","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41575-019-0196-9","article-title":"Restoring, releasing or replacing adaptive immunity in chronic hepatitis B","volume":"16","author":"Maini","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2024.05.004_bib82","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3350\/cmh.2022.0342","article-title":"Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection","volume":"29","author":"Lin","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.livres.2024.05.004_bib83","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S2468-1253(20)30249-1","article-title":"Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis","volume":"5","author":"Tseng","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2024.05.004_bib84","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2024.05.004_bib85","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/liv.13253","article-title":"Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients","volume":"36","author":"Su","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.livres.2024.05.004_bib86","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.livres.2024.05.004_bib87","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","article-title":"Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection","volume":"60","author":"Buti","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.livres.2024.05.004_bib88","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/cncr.29537","article-title":"Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"121","author":"Kim","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.livres.2024.05.004_bib89","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2014.10.035","article-title":"Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection","volume":"62","author":"Agarwal","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2024.05.004_bib90","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2024.05.004_bib91","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2024.05.004_bib92","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2019.09.025","article-title":"Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China","volume":"158","author":"Yip","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.livres.2024.05.004_bib93","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12885-022-09413-7","article-title":"Risk of hepatocellular carcinoma in antiviral treatment-na\u00efve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis","volume":"22","author":"Huang","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.livres.2024.05.004_bib94","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jhep.2022.12.007","article-title":"Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: individual patient data meta-analysis","volume":"78","author":"Choi","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2024.05.004_bib95","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41598-020-80523-7","article-title":"Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B","volume":"11","author":"Chang","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.livres.2024.05.004_bib96","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000518940","article-title":"Tenofovir is superior to entecavir on tertiary prevention for BCLC stage 0\/A hepatocellular carcinoma after curative resection","volume":"11","author":"Tsai","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.livres.2024.05.004_bib97","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.31289","article-title":"Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection","volume":"73","author":"Choi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2024.05.004_bib98","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3390\/cancers16050887","article-title":"Reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B receiving long-term besifovir therapy","volume":"16","author":"Yim","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.livres.2024.05.004_bib99","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3390\/v14020434","article-title":"Current trend in antiviral therapy for chronic hepatitis B","volume":"14","author":"Chien","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.livres.2024.05.004_bib100","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","article-title":"Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: finite treatment duration unlikely","volume":"58","author":"Chevaliez","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2024.05.004_bib101","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s12072-019-09989-6","article-title":"Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift","volume":"13","author":"Liaw","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.livres.2024.05.004_bib102","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/infdis\/jiab241","article-title":"Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis B","volume":"224","author":"Hsu","year":"2021","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.livres.2024.05.004_bib103","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jhep.2009.04.003","article-title":"Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia","volume":"51","author":"Liaw","year":"2009","journal-title":"J\u00a0Hepatol"}],"container-title":["Liver Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542568424000199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542568424000199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T12:59:45Z","timestamp":1719665985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542568424000199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":103,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2542568424000199"],"URL":"https:\/\/doi.org\/10.1016\/j.livres.2024.05.004","relation":{},"ISSN":["2542-5684"],"issn-type":[{"value":"2542-5684","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B virus as a risk factor for hepatocellular carcinoma: There is still much work to do","name":"articletitle","label":"Article Title"},{"value":"Liver Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.livres.2024.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Third Affiliated Hospital of Sun Yat-sen University. Publishing services by Elsevier B. V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}]}}